{
    "id": 25428,
    "fullName": "NF2 R198*",
    "impact": "nonsense",
    "proteinEffect": "loss of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "NF2 R198* results in a premature truncation of the Nf2 protein at amino acid 198 of 595 (UniProt.org). R198* is predicted to lead to a loss of Nf2 protein function.has not been biochemically characterized however, due to the effects of truncation mutations downstream of R198 (PMID: 19910496, PMID: 31257748), is predicted to lead to a loss of Nf2 protein function.",
            "references": [
                {
                    "id": 17549,
                    "pubMedId": 19910496,
                    "title": "Tumor-suppression functions of merlin are independent of its role as an organizer of the actin cytoskeleton in Schwann cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19910496"
                },
                {
                    "id": 17214,
                    "pubMedId": 31257748,
                    "title": "Expression of NF2 Modulates the Progression of BRAFV600E Mutated Thyroid Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31257748"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4771,
        "geneSymbol": "NF2",
        "terms": [
            "NF2",
            "ACN",
            "BANF",
            "SCH"
        ]
    },
    "variant": "R198*",
    "createDate": "09/26/2016",
    "updateDate": "01/15/2020",
    "referenceTranscriptCoordinates": {
        "id": 88775,
        "transcript": "NM_000268",
        "gDna": "chr22:g.29655669C>T",
        "cDna": "c.592C>T",
        "protein": "p.R198*",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8524,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, loss-of-function mutations of NF2 including NF2 R198* and a splice-site mutation that affects the FERM domain were identified in a lung adenocarcinoma patient harboring EGFR L858R and T790M, who acquired resistance to Gilotrif (afatinib) and Erbitux (cetuximab) combination treatment (PMID: 24813888).",
            "molecularProfile": {
                "id": 26919,
                "profileName": "EGFR T790M EGFR L858R NF2 R198*"
            },
            "therapy": {
                "id": 4190,
                "therapyName": "Afatinib + Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 4088,
                    "pubMedId": 24813888,
                    "title": "Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24813888"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26346,
            "profileName": "NF2 R198*",
            "profileTreatmentApproaches": [
                {
                    "id": 11173,
                    "name": "EGFR Inhibitor (Pan)",
                    "profileName": "NF2 R198*"
                },
                {
                    "id": 11172,
                    "name": "mTORC1 Inhibitor",
                    "profileName": "NF2 R198*"
                },
                {
                    "id": 11168,
                    "name": "mTOR Inhibitor",
                    "profileName": "NF2 R198*"
                },
                {
                    "id": 11169,
                    "name": "Bevacizumab",
                    "profileName": "NF2 R198*"
                },
                {
                    "id": 11171,
                    "name": "PDGFR Inhibitor (Pan)",
                    "profileName": "NF2 R198*"
                },
                {
                    "id": 11170,
                    "name": "VEGFR Inhibitor (Pan)",
                    "profileName": "NF2 R198*"
                }
            ]
        },
        {
            "id": 26919,
            "profileName": "EGFR T790M EGFR L858R NF2 R198*",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 88776,
            "transcript": "NM_181825",
            "gDna": "chr22:g.29655669C>T",
            "cDna": "c.592C>T",
            "protein": "p.R198*",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 88774,
            "transcript": "NM_016418",
            "gDna": "chr22:g.29655669C>T",
            "cDna": "c.592C>T",
            "protein": "p.R198*",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 88773,
            "transcript": "NM_181832",
            "gDna": "chr22:g.29655669C>T",
            "cDna": "c.592C>T",
            "protein": "p.R198*",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 88775,
            "transcript": "NM_000268",
            "gDna": "chr22:g.29655669C>T",
            "cDna": "c.592C>T",
            "protein": "p.R198*",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}